Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BIRC5 (Baculoviral IAP repeat containing 5)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Labcorp® Plasma Complete™

Labcorp® Plasma Complete™

›

BIRC5 expression	Diffuse Large B Cell Lymphoma	BIRC5 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria pembrolizumab + MVP-S Sensitive : C2	pembrolizumab + MVP-S Sensitive: C2 – Inclusion Criteria pembrolizumab + MVP-S Sensitive : C2
BIRC5 expression	Non Small Cell Lung Cancer	BIRC5 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
BIRC5 expression	Bladder Cancer	BIRC5 expression	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
BIRC5 overexpression	HER2 Positive Breast Cancer	BIRC5 overexpression	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
BIRC5 rs8073069	Non Small Cell Lung Cancer	BIRC5 rs8073069	Non Small Cell Lung Cancer	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
BIRC5 rs8073069	Non Small Cell Lung Cancer	BIRC5 rs8073069	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3
BIRC5 rs8073069	Non Small Cell Lung Cancer	BIRC5 rs8073069	Non Small Cell Lung Cancer	cisplatin + vinorelbine tartrate Sensitive: C3 – Early Trials cisplatin + vinorelbine tartrate Sensitive : C3	cisplatin + vinorelbine tartrate Sensitive: C3 – Early Trials cisplatin + vinorelbine tartrate Sensitive : C3
BIRC5 overexpression	Non Small Cell Lung Cancer	BIRC5 overexpression	Non Small Cell Lung Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials carboplatin + paclitaxel Sensitive : C3	carboplatin + paclitaxel Sensitive: C3 – Early Trials carboplatin + paclitaxel Sensitive : C3
BIRC5 mutation	Glioblastoma	BIRC5 mutation	Glioblastoma	temozolomide Sensitive: D – Preclinical temozolomide Sensitive : D	temozolomide Sensitive: D – Preclinical temozolomide Sensitive : D